SCHEMBL5223968

SCHEMBL5223968

CC(C)COC(=O)N1CCC(N2CCc3cc(S(=O)(=O)c4ccccc4)ccc32)CC1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.49
CHRM1 P11229 2/20 0.49
GPR119 Q8TDV5 8/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228645 0.92 CHRM2 (0.48) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL5198338 0.90 CHRM2 (0.51) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL5198989 0.89 CHRM2 (0.46) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL5196493 0.89 GPR119 (0.45) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL5199608 0.85 GPR119 (0.49) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL5199217 0.85 CHRM2 (0.45) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL5304121 0.84 GPR119 (0.46) CHRM2CHRM1GPR119SMN1; SMN2LMNA
SCHEMBL4894257 0.84 GPR119 (0.52) GPR119
SCHEMBL3941601 0.83 OPRM1 (0.51)
SCHEMBL5197149 0.81 GPR119 (0.41) CHRM2CHRM1GPR119SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814873-A2 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2007-08-08 EP disclosed
WO-2006038006-A2 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2006-04-13 WO disclosed